Anti-tumor necrosis factor-alpha treatment in pediatric patients with pars planitis: a single-center experience from Turkey.
Int Ophthalmol
; 43(1): 155-166, 2023 Jan.
Article
in En
| MEDLINE
| ID: mdl-35780435
ABSTRACT
AIM:
To evaluate the effectiveness and safety of anti-tumor necrosis factor-alpha (anti-TNF-alpha) treatment (Adalimumab [ADA]) combined with immunomodulatory agents (IMAs) in the treatment of pars planitis (PP).METHODS:
The patients with PP who were treated with anti-TNF-alpha agents for at least six months were qualified for the chart review. The outcome parameters were the steroid-free remission state, the best-corrected visual acuity (BCVA) and the central macular thickness (CMT) of the patients at the last visit.RESULTS:
After a mean total follow-up time of 15.5 ± 5.8 months (8-24 months), all the cases were in steroid-free remission at the last visit. The mean BCVA increased, and the mean CMT decreased significantly at the last visit (p < 0.001, p < 0.001, respectively).CONCLUSION:
ADA combined with IMAs offers effective and safe treatment modalities in the control of chronic intraocular inflammation in PP cases.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pars Planitis
/
Adalimumab
/
Tumor Necrosis Factor Inhibitors
Limits:
Child
/
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Int Ophthalmol
Year:
2023
Document type:
Article
Affiliation country:
Turkey